Hepatitis B virus vaccine

Specificity Reacts with HBcAg (epitope recognized - amino acid positions 135-140). SPECIES REACTIVITIES: Cross-reacts with woodchuck hepatitis virus core antigen (WHcAg), but not with duck hepatitis B virus core antigen (DHBcAg).

Specificity Reacts with Hbx protein (trans-activator X gene product) of hepatitis B virus (epitope recognized - amino acid positions 50-88). SPECIES REACTIVITIES: Reacts only with human HBV Immunogen Epitope: X-Protein, aa50-88 Peptide

General description Hepatitis B virus surface antigen is one of the earliest markers of infection with hepatitis B virus. Hepatitis B virus surface antigen is tested for in the differential diagnosis of hepatitis.

General description Large envelope protein (UniProt: A7XR30: also known as L glycoprotein, L-HBsAg, LHB, Large S protein, Large surface protein, Major surface antigen) is encoded by the S (also known as Large S, P, preS1, preS2) gene (Gene ID:

General description Large envelope protein (UniProt: A7XR30: also known as L glycoprotein, L-HBsAg, LHB, Large S protein, Large surface protein, Major surface antigen) is encoded by the S (also known as Large S, P, preS1, preS2) gene (Gene ID:

General description Hepatitis B virus (HBV) is a small DNA virus belonging to the hepadnavirus family and is believed to the causative agent of type B hepatitis. The Hepatitis B surface antigen (HBsAg) is a protein antigen produced by HBV.

AT-130, a phenylpropenamide derivative, is a potent hepatitis B virus (HBV) replication non-nucleoside inhibitor. AT-130 inhibits the viral DNA synthesis with an EC 50 of 0.13 μM. AT-130 inhibits both wt and mutant HBVs. AT-130 has anti-HBV activity

AT-130, a phenylpropenamide derivative, is a potent hepatitis B virus (HBV) replication non-nucleoside inhibitor. AT-130 inhibits the viral DNA synthesis with an EC 50 of 0.13 μM. AT-130 inhibits both wt and mutant HBVs. AT-130 has anti-HBV activity

AT-130, a phenylpropenamide derivative, is a potent hepatitis B virus (HBV) replication non-nucleoside inhibitor. AT-130 inhibits the viral DNA synthesis with an EC 50 of 0.13 μM. AT-130 inhibits both wt and mutant HBVs. AT-130 has anti-HBV activity

AT-130, a phenylpropenamide derivative, is a potent hepatitis B virus (HBV) replication non-nucleoside inhibitor. AT-130 inhibits the viral DNA synthesis with an EC 50 of 0.13 μM. AT-130 inhibits both wt and mutant HBVs. AT-130 has anti-HBV activity

AT-130, a phenylpropenamide derivative, is a potent hepatitis B virus (HBV) replication non-nucleoside inhibitor. AT-130 inhibits the viral DNA synthesis with an EC 50 of 0.13 μM. AT-130 inhibits both wt and mutant HBVs. AT-130 has anti-HBV activity

BA-53038B is a HBV core protein allosteric modulator (CpAM) , binding to the HAP pocket and modulating HBV capsid assembly. BA-53038B has antiviral activity for hepatitis B virus (HBV) with an EC 50 value of 3.32 μM. BA-53038B can be used for the